English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Long-Acting Reversible Contraception methods (LARCs) have a lower uptake rate than oral contraception, despite being more reliable and potentially cheaper in the long run. Historically, high insertion costs have stunted their uptake. The Affordable Care Act eradicated these costs by classifying contraception as preventative care that insurers must offer at no charge as of late 2012. Additionally, the ACA required that all employer-provided insurance plans have contraceptive coverage. After four years of coverage, the 2016 national election represented a credible threat to the ACA and contraceptive coverage and access. Utilizing the National Survey of Family Growth, I estimate how LARC uptake changed during and after 2016 using data from 2011 to 2019. I find that use of LARCs spiked in 2016 and 2017 for Medicaid users and 2017 and 2019 for women with private insurance.

Threats to ACA associated with temporary increase in Long-Acting Reversible Contraception